Details werden geladen...
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | The Manila Times
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy
Ähnliche Seiten
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/krystal-biotech-announces-united-kingdom-mhra-approval-of-vyjuvek-for-the-treatment-of-dystrophic-epidermolysis-bullosa/2346165Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/microbiotica-announces-positive-results-from-its-phase-1b-trial-melody-1-of-mb097-a-precision-microbiome-co-therapy-in-advanced-melanoma/2345933Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet | The Manila Times
https://www.manilatimes.net/2026/05/31/tmt-newswire/pr-newswire/sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-nsclc-published-in-the-lancet/2355083JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/jascayd-nerandomilast-approved-in-japan-advancing-global-access-to-a-new-ipf-and-ppf-treatment/2345863London Specialist Dentists Announce the Use of Ozone Therapy in Periodontal Treatment and Dental Implants | The Manila Times
https://www.manilatimes.net/2026/06/05/tmt-newswire/globenewswire/london-specialist-dentists-announce-the-use-of-ozone-therapy-in-periodontal-treatment-and-dental-implants/2359131